

ATTY. DOCKET NO.
33700W003

SERIAL NO.
09/519998
To Be Assigned PTO

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT
Scott D. Wilbur et al.

FILING DATE
Herewith 3/6/00

GROUP
1619



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,134,071	7/92	Gaetjens	435	188	
	AB	5,310,916	5/94	Jacobson et al.	546	224	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
LQW	AM	WO 89/10140	11/89	PCT				
	AN	WO 97/29114	8/97	PCT				
	AO	WO 93/02105	2/93	PCT				
LQW	AP	0 310 361	4/89	EPO				
	AQ	0 618 192 A1	10/94	EPO				
	AR	WO 00/02050	01/00	PCT				
	AS	WO 96/04313	02/96	PCT				

OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

AT	Immunotargeting of antioxidant enzymes to the pulmonary endothelium, Proc. Natl Acad. Sci. USA, Vol. 93, pp. 5213-5218, May 1996
AU	PCT Request Form 101, and PCT Form 308 for above-noted WO 00/02050 PCT Publication
AV	American Chemical Society, copyright 1998, page 1


EXAMINER

Sam O. Wells

DATE CONSIDERED

6/8/01

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.



PAGE 1 OF 4

Form PTO-1449
(Rev. 7-80)U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
033700.003SERIAL
09/519,998

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT
Wilber, et alFILING DATE
March 6, 2000GROUP
1616/1619

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LQW	Y	5,134,071	07/1992	Gaetjens			
LQW	Z	5,310,916	05/1994	Jacobson, et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
LQW	AA	WO 96/04313	02/1996	WIPO			✓	
	AB	EP 618 192 A1	10/1994	EPO				X
LQW	AC	EP 310 361 A2	04/1989	EPO			✓	
	AD	WO 93/02105	02/1993	WIPO			✓	
	AE	WO 97/29114	08/1997	WIPO			✓	
LQW	AF	WO 89/10140	11/1989	WIPO			✓	
							✓	

OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

LQW	AG	"Immunotargeting of antioxidant enzymes to the pulmonary endothelium," authored by Vladimir R. Muzykantov, et al., featured in <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93, May 1996, pp. 5213-5218
	AH	"Development of a Streptavidin - Anti-Carcinoembryonic Antigen, Antibody, Radiolabeled Biotin Pretargeting Method for Radioimmunotherapy of Colorectal Cancer. Studies in a Human Colon Cancer Xenograft Model," authored by Robert M. Sharkey, et al., featured in <i>Bioconjugate Chem.</i> , Vol. 8, No. 4, 1997, pp. 595-604
	AI	"Rapid Blood Clearance of Biotinylated IgG after Infusion of Avidin," authored by Vladimir V. Sinitsyn, et al., featured in <i>The Journal of Nuclear Medicine</i> , Vol. 30, No. 1, January, 1989, pp. 66-69
	AJ	"Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab') ₂ fragments of an anti-tumour antibody," authored by D. Marshall, et al., featured in <i>British Journal of Cancer</i> , Vol. 71, 1995, pp. 18-24
	AK	"The Role of Surface Carbohydrates in the Hepatic Recognition and Transport of Circulating Glycoproteins," authored by Gilbert Ashwell, et al., featured in <i>Adv. Enzymol.</i> , Vol. 41, 1974, pp. 99-128. (Ref Missing)
	AL	"Strategies to Enhance the Localization of Anticancer Immunoconjugates," authored by George J. Schreiber, et al., featured in <i>Current Medicinal Chemistry</i> , Vol. 2, 1995, pp. 616-629
LQW	AM	"Improved Monoclonal Antibody Tumor/Background Ratios with Exchange Transfusions," authored by Christine A. Henry, et al., featured in <i>Nucl. Med. Biol.</i> Vol. 18, No. 5, 1991, pp. 565-567

EXAMINER

Lauren P. Wells

DATE CONSIDERED

6/8/01

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Form PTO-1449
Rev. 7-80)U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
033700.003SERIAL NO.
09/519,998

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT
Wilber, et alFILING DATE
March 6, 2000GROUP
16167 1619

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

LQW	AN	"Improved Tumor Imaging with Radiolabeled Monoclonal Antibodies by Plasma Clearance of Unbound Antibody with Anti-antibody Column," authored by James L. Lear, MD, et al., featured in <i>Radiology</i> , Vol. 179, 1991, pp. 509-512
	AO	"Radioimmunoabsorption of KC-4G3 Antibody in Peripheral Blood: Implications for Radioimmunotherapy," authored by Timothy K. Johnson, et al., featured in <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 4, 1991, pp. 885-893
	AP	"Extracorporeal Immunoabsorption of Radiolabeled Monoclonal Antibody: A method for Reduction of Background Radioactivity and Its Potential Role During the Radioimmunotherapy of Cancer," authored by David G. Dienhart, et al., featured in <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 7, No. 4, 1994, pp. 225-252
	AQ	"Immunoabsorption: An Enhancement Strategy for Radioimmunotherapy," authored by Gerald L. DeNardo, et al., featured in <i>The Journal of Nuclear Medicine</i> , Vol. 34, No. 6, June, 1993, pp. 1020-1027
	AR	"Biotin Reagents for Antibody Pretargeting. Synthesis, Radioiodination, and in Vitro Evaluation of Water Soluble, Biotinidase Resistant Biotin Derivatives," authored by D. Scott Wilbur, et al., featured in <i>Bioconjugate Chem.</i> , Vol. 8, 1997, pp. 572-584
	AS	"A General, Extracorporeal Immunoabsorption Method to Increase the Tumor-to-Normal Tissue Ratio in Radioimmunotherapy and Radioimmunotherapy," authored by Kristina Norrgren, et al., featured in <i>The Journal of Nuclear Medicine</i> , Vol. 34, No. 3, March, 1993, pp. 448-454
LQW	AT	"Extracorporeal Whole-Blood Immunoabsorption Enhances Radioimmunotargeting of Iodine-125-Labeled BR96-Biotin Monoclonal Antibody," authored by Michael Garkavij, et al., featured in <i>The Journal of Nuclear Medicine</i> , Vol. 38, No. 6, June, 1997, pp. 895-901

EXAMINER

Lauron G. Wells

DATE CONSIDERED

6/8/01

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Form PTO-1449
Rev. 7-80)U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
033700.003SERIAL NO.
09/519,998

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT
Wilber, et alFILING DATE
March 6, 2000

GROUP

2616/1121

RECEIVED
JAN 12 2001
TECHNICAL
GROUP
2616/1121

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

LQW	AU	"Extracorporeal Immunoabsorption From Whole-Blood Based on the Avidin-Biotin Concept Evaluation of a New Method," authored by Michael Garkavij, et al., featured in <i>Acta Oncologica</i> , Vol. 35, No. 3, 1996, pp. 309-312
	AV	"Evaluation of Extracorporeal Immunoabsorption for Reduction of the Blood Background in Diagnostic and Therapeutic Applications of Radiolabeled Monoclonal Antibodies" authored by Kristina Norrgren, et al., featured in <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 4, 1991, pp. 907-914
	AW	<i>Radionuclides in Therapy</i> , edited by Richard P. Spencer, et al., 1987 (Table of Contents included)
	AX	"Radionuclide Production for the Biosciences," authored by T.J. Ruth, et al., featured in <i>Nucl. Med. Biol.</i> , Vol. 16, No. 4, 1989, pp. 323-336
	AY	"Biotinidase," authored by Barry Wolf, et al., featured in <i>Methods in Enzymology</i> , Vol. 184, 1990, pp. 103-111
LQW	AZ	"Animal Biotinidase," authored by Jaakko Pispä, featured in <i>Annales Medicinæ Experimentalis Et Biologiæ Fenniae</i> , Vol. 43, 1965, Suppl. 5, pp. 1-39

EXAMINER

Laurin Q. Wells

DATE CONSIDERED

6/8/01

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Form PTO-1449
Rev. 7-80)U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
033700.003SERIAL NO.
09/519,998

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT
Wilber, et alFILING DATE
March 6, 2000GROUP
1616RECEIVED
JAN 10 2001
TELETYPE UNIT 1600/2300

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

LQW	BA	"Plasma Stability and Pharmacokinetics of Radiolabeled Deferoxamine-Biotin Derivatives," authored by Scott F. Rosebrough., featured in <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 265, No. 1, 1993, pp. 408-415
	BB	"Scientific Papers - Proceedings of the 39 th Annual Meeting (Wednesday)," featured in <i>The Journal of Nuclear Medicine</i> , Vol. 33, No. 5, May, 1992, pp. 862-864
	BC	"Immunology," featured in <i>Proceedings of AACR</i> , Vol. 28, March 1987, p. 391
	BD	"Decreased renal accumulation of biotinylated chimeric monoclonal antibody-neocarzinostatin conjugate after administration of avidin", authored by Otusji, et al., featured as an ABSTRACT in the American Chemical Society, 1998, p. 1
MQW	BE	"Radiolabeling of Monoclonal Antibodies with Metal Chelates," featured in <i>Pure & Appl. Chem</i> , Vol. 63, No. 3, 1991, pp. 427-463

EXAMINER

Laurin Q. Wilber

DATE CONSIDERED

6/8/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Form PTO-1449
(Rev. 7-80)U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
033700.003SERIAL NO.
09/519,998

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT

Wilber, et al

FILING DATE

March 6, 2000

GROUP

1616 1619

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LOE	A	5,474,772	12/1995	Maddock			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
LQW	B	EP 0 567 514 B1	11/1993	Europe			✓	
	C	WO91/01749	02/1991	PCT			✓	
LQW	D	AU-B-64268/90	03/1991	Australia			✓	

OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

LQW	E	"Radioimmunoscinigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer," authored by M. Granowska, et al., featured in <i>European Journal of Nuclear Medicine</i> , Vol. 20, No. 6, June 1993, pp. 483-489						
	F	"Radioimaging of Melanoma Using ^{99m} Tc-labeled Fab Fragment Reactive with a High Molecular Weight Melanoma Antigen," authored by Lamk M. Lamki, et al., featured in <i>Cancer Research (Suppl.)</i> , 50, February 1, 1990, pp. 904s-908s						
	G	"Clinical Studies of Cancer Radioimmunodetection with Carcinoembryonic Antigen Monoclonal Antibody Fragments Labeled with ¹²³ I or ^{99m} Tc," authored by David M. Goldenberg, et al., featured in <i>Cancer Research (Suppl.)</i> , 50, February 1, 1990, pp. 909s-921s						
	H	"Clinical Experience with Iodine-123-Iodophenylpentadecanoic Acid," authored by James Corbett, featured in <i>The Journal of Nuclear Medicine</i> , Vol. 35, No. 4 (Suppl), April, 1994, pp. 32S-37S						
	I	"Preliminary Report of an Ongoing Phase I/II Dose Range, Safety and Efficacy Study of Iodine-123-Phenylpentadecanoic Acid for the Identification of Viable Myocardium," authored by C. Hansen, featured in <i>The Journal of Nuclear Medicine</i> , Vol. 35, No. 4 (Suppl), April, 1994, pp. 38S-42S						
	J	"Localization of Cognitive Operations in the Human Brain," authored by Michael I. Posner, et al., featured in <i>Science</i> , Vol. 240, June 17, 1988, pp.1627-1631						
LQW	K	"Cardiac SPECT with Iodine-123-Labeled Fatty Acids: Evaluation of Myocardial Viability with BMIPP," authored by F.F. (Russ) Knapp, et al., featured in <i>The Journal of Nuclear Medicine</i> , Vol. 36, No. 6, June, 1995, pp. 1022-1030						

EXAMINER

Karen Q. Walker

DATE CONSIDERED

6/8/01

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Form PTO-1449
(Rev. 7-80)U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
033700.003SERIAL NO.
09/519,998

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT
Wilber, et alFILING DATE
March 6, 2000GROUP
~~1615~~ 1619

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

LQW	L	"Phase I/II Clinical Radioimmunotherapy with an Iodine-131-Labeled Anti-Carcinoembryonic Antigen Murine Monoclonal Antibody IgG," authored by Thomas M. Behr, et al., featured in <i>The Journal of Nuclear Medicine</i> , Vol. 38, No. 6 June, 1997, pp. 858-870
	M	"Phase I Radioimmunotherapy Trial with Iodine-131-CC49 in Metastatic Colon Carcinoma," authored by C.R. Divgi, et al., featured in <i>The Journal of Nuclear Medicine</i> , Vol. 36, No. 4 April, 1995, pp. 586-592
	N	"Yttrium-90/Indium-111-DOTA-Peptide-Chimeric L6: Pharmacokinetics, Dosimetry and Initial Results in Patients with Incurable Breast Cancer," authored by Sally J. Denardo, et al., featured in <i>Anticancer Research</i> , Vol. 17, 1997, pp. 1735-1744
	O	"Experimental Radiotherapy of Receptor-Positive Human Prostate Adenocarcinoma With ¹⁸⁸ Re-RC-160, A Directly-Radiolabeled Somatostatin Analogue," authored by Paul O. Zamora, et al., featured in <i>Int. J. Cancer</i> , Vol. 65, 1996, pp. 214-220
	P	"Regulation of Tumor Cell Growth: Experimental Approaches and Clinical Oncology -- Somatostatin Analogues for Somatostatin-Receptor-Mediated Radiotherapy of Cancer," authored by B. Stolz, et al., featured in <i>Digestion</i> , Vol. 57 (suppl 1), 1996, pp. 17-21
	Q	"ZD2767, an Improved System for Antibody-directed Enzyme Prodrug Therapy That Results in Tumor Regressions in Colorectal Tumor Xenografts," authored by David C. Blakey, et al., featured in <i>Cancer Research</i> , Vol. 56, July 15, 1996, pp. 3287-3292
LQW	R	"Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model," authored D. Marshall, et al., featured in <i>Br. J. Cancer</i> , Vol. 69, 1994, pp. 502-507

EXAMINER

LQW

DATE CONSIDERED

6/8/01

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

RECEIVED

OCT 19 2000

TECH CENTER 1500/2000

Form PTO-1449
(Rev. 7-80)U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
033700.003SERIAL NO.
09/519,998

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT
Wilber, et alFILING DATE
March 6, 2000GROUP
~~1616~~ 1619

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

AQW	S	"Clinical Aspects of Local and Regional Tumor Therapy with ¹⁸⁸ Re-RC-160," authored by H. Bender, et al., featured in <i>Anticancer Research</i> , Vol. 17, 1997, pp. 1705-1712
	T	"Blood Clearance of Radiolabeled Antibody: Enhancement by Lactosamination and Treatment with Biotin-Avidin or Anti-Mouse IgG Antibodies," authored by Alexander L. Klivanov, et al., featured in <i>The Journal of Nuclear Medicine</i> , Vol. 29, No. 12, December, 1998, pp. 1951-1956
	U	"Improved Characteristics of a Human β -Glucuronidase-Antibody Conjugate after Deglycosylation for Use in Antibody-Directed Enzyme Prodrug Therapy," authored by Pieter H. J. Houba, et al., featured in <i>Bioconjugate Chem.</i> , Vol. 7, No. 5, 1996, pp. 606-611
	V	"Site-Specific Prodrug Activation by Antibody- β -Lactamase Conjugates: Preclinical Investigation of the Efficacy and Toxicity of Doxorubicin Delivered by Antibody Directed Catalysis," authored by Damon L. Meyer, et al., featured in <i>Bioconjugate Chem.</i> , Vol. 6, No. 4, 1995, pp. 440-446
LW	W	"Avidin and Streptavidin," authored by N. Michael Green, featured in <i>Methods in Enzymology</i> , Vol. 184, 1990, pp. 51-67
	X	"Avidin," authored by N. Michael Green, featured in <i>Adv. Prot. Chem.</i> , Vol. 29, 1975, pp. 85-132.

EXAMINER

Lauren G. Welke

DATE CONSIDERED

6/8/01

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

RECEIVED

OCT 19 2000

TECH CENTER 1800/2000